Zobrazeno 1 - 10
of 167
pro vyhledávání: '"11"'
Autor:
Alexa J. Siddon, Thomas Prebet, Scott F. Huntington, Jan Philipp Bewersdorf, Stephanie Halene, Francine M. Foss, Noffar Bar, Natalia Neparidze, Amer M. Zeidan, Rory M. Shallis, Iris Isufi, Terri L. Parker, Nikolai A. Podoltsev, Stuart Seropian, Tae Kon Kim, Manoj M. Pillai, Steven D. Gore, Autumn DiAdamo, Lohith Gowda
Publikováno v:
Blood. 134:5174-5174
Introduction: Isolated trisomy 11 is a rare, poorly characterized cytogenetic abnormality in myeloid neoplasms (MN) with only a few case series published. Prior reports suggested a lower response rate to standard treatments such as intensive chemothe
Autor:
Chao Niu, Sai-Juan Chen, Xiao-Ying Zeng, Mei-Yu Ren, Zhu Chen, Jian-Xiang Liu, Zhen-Yi Wang, Yu Ting, Huiping Sun, Ting-Dong Zhang, Xiu-Song Li, Samuel Waxman, Feng-Ying Gu, Qi Cao, Shu-Min Xiong, Hua Yan, Mi-Man Yuan, Jiong Hu, Xin-Ying Su, Guo-Qiang Chen, Wen Wu, Junmin Li, Bo-Wei Gu, Ren-Rong Ou Yang, Yu Chen, Li Zhou, Fen-Qin Zhang, Zhi-Xiang Shen
Publikováno v:
Blood. 94(10)
Fifty-eight acute promyelocytic leukemia (APL) patients (11 newly diagnosed and 47 relapsed) were studied for arsenic trioxide (As2O3) treatment. Clinical complete remission (CR) was obtained in 8 of 11 (72.7%) newly diagnosed cases. However, As2O3 t
Autor:
Craig C. Hofmeister, Lawrence H. Boise, Ryosuke Shirasaki, Jonathan L. Kaufman, Nisha Joseph, Benjamin G. Barwick, David L. Jaye, Jonathan J Keats, Constantine S. Mitsiades, Leonard T. Heffner, Benjamin Oberlton, Ajay K. Nooka, Vikas Gupta, Sagar Lonial, Shannon M. Matulis, Madhav V. Dhodapkar
Publikováno v:
Blood. 137:3604-3615
Venetoclax is a highly potent, selective BCL2 inhibitor capable of inducing apoptosis in cells dependent on BCL2 for survival. Most myeloma is MCL1-dependent; however, a subset of myeloma enriched for translocation t(11;14) is codependent on BCL2 and
Autor:
Winfried F. Pickl, Sabine Cerny-Reiterer, Michael Kneidinger, Matthias Mayerhofer, Christian Sillaber, Karl J. Aichberger, Alexander Gruze, Veronika Ferenc, Irina Mirkina, Peter Valent, Barbara Peter, Karoline V. Gleixner, Christian Baumgartner
Publikováno v:
Blood. 114(26)
Systemic mastocytosis (SM) is a myeloid neoplasm involving mast cells (MCs) and their progenitors. In most cases, neoplastic cells display the D816V-mutated variant of KIT. KIT D816V exhibits constitutive tyrosine kinase (TK) activity and has been im
Autor:
Selina M. Luger, Alison W. Loren, Imran Ajmal, James K. Mangan, Noelle V. Frey, Elizabeth O. Hexner, Martin Carroll
Publikováno v:
Blood. 134:5155-5155
Although deferasirox use is established in clinical practice for iron overload, there have been a spate of case reports describing hematologic improvement attributed to use of this agent in myelodysplastic syndrome (MDS) patients (Guariglia et al, Le
Autor:
Grace Perry, Genique Stanislaus, Joelle Gagnon, Yen-Hong Kuo, Danielle Marcotulli, Maritess Aviador, James K. McCloskey, Jamie Koprivnikar, Elizabeth Jones
Publikováno v:
Blood. 132:2703-2703
Background: Blinatumumab (B), a bi-specific T-cell engaging CD3-CD19 antibody construct, has shown significant activity in patients (pts) with B-cell acute lymphoblastic leukemia (B-ALL). Despite this improvement, uncertainties remain regarding the o
Autor:
Lubov Grebenyuk, Murat Vagida, Elena A. Mikhaylova, Tatiana N. Obukhova, Yuliya O. Davydova, Tatiana I. Lobanova, Anton V. Luchkin, Anastasia V. Abramova, Alina E. Krasilnikova, Valery G. Savchenko, Elena N. Parovichnikova, Irina V. Galtseva, Vera V. Troitskaya, Zalina T. Fidarova, Nikolay M. Kapranov
Publikováno v:
Blood. 132:5108-5108
Background. New insight into pathogenesis of aplastic anemia (AA) in conjunction with effectiveness of Eltrombopag allowes to recommend it for initial treatment of de novo AA. However, eltrombopag was an attractive option for patients at different st
Autor:
Yvette Bernal, Richard R. Furman, Maria Lia Palomba, John Pineda, Isabelle Riviere, Brigitte Senechal, Malloury Hall, Michel Sadelain, Jae H. Park, Claudia Diamonte, Renier J. Brentjens, Xiuyan Wang, Elizabeth Halton, Connie Lee Batlevi
Publikováno v:
Blood. 132:224-224
Background: CD19-specific 2nd generation chimeric antigen receptor (CAR) T cell therapy with either CD28 or 41BB co-stimulatory domain has demonstrated complete remission (CR) rates of 30-50% in relapsed or refractory (R/R) NHL and 20-30% in CLL. The
Autor:
Simon Danisch, Renata Stripecke, Felicitas Thol, Michael Heuser, Arnold Kloos, Razif Gabdoulline, Renate Schottmann, Konstantinos Mintzas, Arnold Ganser
Publikováno v:
Blood. 132:3933-3933
INTRODUCTION On average 5 recurrent mutations are present in each patient with acute myeloid leukemia (AML). Many mutated genes are implicated as tumor suppressor genes, but their contribution to leukemia stem cell (LSC) survival and chemoresistance
Autor:
Lugui Qiu, Shilian Chen, Yongjun Guan, Wen Zhou, Jiliang Xia, Jingyu Zhang, Jiaojiao Guo, Minghua Wu, Wu Xuan, Fenghuang Zhan, Jingchao Lin, Mingming Su
Publikováno v:
Blood. 132:3163-3163
E-mail: wenzhou@csu.edu.cn Background: Metabolism reprogramming is one of ten features in cancer. It is well known that metabolites in tumor microenvironment contribute to the survival and proliferation of cancer cells. Currently, a lack of detailed